SCHEMBL6575575

SCHEMBL6575575

CCN(C)CCc1ccc(OC)c(OC)c1

nearest known ligand 0.83

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.83
CYP3A4 P08684 2/20 0.83
CYP2D6 P10635 2/20 0.83
BLM P54132 2/20 0.81
PMP22 Q01453 1/20 0.81
ALDH1A1 P00352 3/20 0.69
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
AOC3 Q16853 1/20 0.68
KDM4E B2RXH2 6/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
SMPD1 P17405 3/20 0.59
CYP2C9 P11712 1/20 0.58
ATM Q13315 2/20 0.56
CA2 P00918 1/20 0.53
POLB P06746 1/20 0.53
CYP19A1 P11511 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7430428 0.91 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL22186872 0.90 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6BLMPMP22
Hydrochloric Acid SCHEMBL29651387 0.89 BLM (1.00) CYP1A2CYP3A4CYP2D6BLMPMP22
Hydrochloric Acid SCHEMBL7194533 0.89 BLM (1.00) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL7290182 0.88 CYP1A2 (0.87) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL18239557 0.86 CYP3A4 (0.90) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL13969525 0.85 CYP3A4 (0.81) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL7314691 0.85 CYP1A2 (0.81) CYP1A2CYP3A4CYP2D6BLMPMP22
SCHEMBL21623605 0.84 CYP1A2 (0.69) CYP1A2CYP3A4CYP2D6BLMPMP22
Hydrochloric Acid SCHEMBL10875595 0.84 PMP22 (0.82) CYP1A2CYP3A4CYP2D6BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160312253-A1 Compounds for Increasing Lipid Synthesis and Storage INVITROGEN CORPORATION 2016-10-27 US disclosed
EP-2108642-A1 JAK INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2009-10-14 EP disclosed
EP-0775689-B9 NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC C & C RES LABS (KR) 2004-09-15 EP disclosed
EP-0775689-B1 NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC C & C RES LABS (KR) 2003-09-03 EP disclosed
US-6057358-A POTASSIUM CHANNEL BLOCKING ANTIARRHYTHMIC DRUGS WITH LESS SIDE EFFECTS C&C RESEARCH LABS. (KR) 2000-05-02 US disclosed
EP-0775689-A1 NOVEL AMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF AS ANTIARRHYTHMIC C & C RESEARCH LABS. (KR) 1997-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160312253-A1 Compounds for Increasing Lipid Synthesis and Storage FASN, LIPC, SREBF2 CYP1A2 1503/4885CYP3A4 1703/4885CYP2D6 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.